Observational studyMedicine2026
Study on the application of serological indicators combined with ultrasonic cardiogram in predicting recurrence of radiofrequency ablation in atrial fibrillation patients.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is associated with high rates of recurrence after radiofrequency ablation (RFA). This retrospective observational study was conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology statement to evaluate whether combined serological and echocardiographic indicators predict postablation recurrence. We retrospectively reviewed 97 nonvalvular AF patients who underwent 1st-time RFA at our institution between April 2021 and April 2023. Patients were classified into recurrence (n = 21) and nonrecurrence (n = 76) groups based on documented AF recurrence within 12 months. Data collection followed prespecified variable definitions: demographic and clinical characteristics, serological markers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and cardiac troponin I [cTnI]), and standardized echocardiographic parameters (left atrial diameter [LAD], left ventricular end-diastolic diameter [LVDD], and left ventricular ejection fraction [LVEF]). We controlled for selection bias by applying strict inclusion/exclusion criteria and blinded measurement of all variables. Logistic regression identified independent predictors of recurrence, and receiver operating characteristic curve analysis quantified predictive performance. After adjustment for confounders, elevated NT-proBNP, cTnI, LAD, and LVDD were independent risk factors (OR range 2.401-3.251; P < .05), while higher LVEF was protective (OR = 0.279; P < .05). The combined model achieved an area under the curve of 0.771 (95% CI: 0.660-0.883; sensitivity 74.1%, specificity 75.7%). In this retrospective study, the combined measurement of NT-proBNP, cTnI, LAD, LVDD, and LVEF demonstrated robust discriminatory power for predicting AF recurrence after RFA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.